Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease

Identifieur interne : 005854 ( Main/Exploration ); précédent : 005853; suivant : 005855

No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease

Auteurs : Ahlskog [États-Unis] ; Ryan J. Uitti [États-Unis] ; Phillip A. Low [États-Unis] ; Gertrude M. Tyce [États-Unis] ; Kim K. Nickander [États-Unis] ; Ronald C. Petersen [États-Unis] ; Emre Kokmen [États-Unis]

Source :

RBID : ISTEX:68B4CB6BF04C2B39FFD316752992C25B4225EAFB

English descriptors

Abstract

Oxidant stress secondary to dopamine metabolism has been proposed as a pathogenic factor in the development of Parkinson's disease. Biochemical abnormalities extending beyond the central nervous system have been identified in patients with this condition. Previous investigators have found abnormally elevated concentrations of the lipid peroxidation product, malondialdehyde, in the plasma and serum of patients with Parkinson's disease. We attempted to replicate these findings but controlled for other factors that could influence malondialdehyde levels. We detected no significant elevations in mean serum malondialdehyde concentrations in either levodopatreated or untreated patients with Parkinson's disease, compared to normal controls; similarly, no elevation was found in a group of patients with dementia of Alzheimer's type. On the other hand, a group of subjects with diabetes mellitus but no neurodegenerative disease had significantly elevated mean serum malondialdehyde levels, consistent with previous studies of diabetic patients. Autoxidation is one of the two major routes by which dopamine and dopa metabolism may generate oxygen free radicals. We analyzed the autoxidation product of dopa, 5‐S‐cysteinyl‐dopa, in the plasma of these same groups of patients with neurodegenerative disease and normal controls; no significant differences were identified. Serum concentrations of two other antioxidant substances, α‐tocopherol and uric acid, were also statistically similar in these groups. In conclusion, analysis of several blood products relevant to oxidant stress, including malondialdehyde, 5‐S‐cysteinyl‐dopa, α‐tocophero, and uric acid, failed to distinguish patients with Parkinson's disease or dementia of Alzheimer's type from controls.

Url:
DOI: 10.1002/mds.870100507


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease</title>
<author>
<name sortKey="Ahlskog" sort="Ahlskog" uniqKey="Ahlskog" last="Ahlskog">Ahlskog</name>
</author>
<author>
<name sortKey="Uitti, Ryan J" sort="Uitti, Ryan J" uniqKey="Uitti R" first="Ryan J." last="Uitti">Ryan J. Uitti</name>
</author>
<author>
<name sortKey="Low, Phillip A" sort="Low, Phillip A" uniqKey="Low P" first="Phillip A." last="Low">Phillip A. Low</name>
</author>
<author>
<name sortKey="Tyce, Gertrude M" sort="Tyce, Gertrude M" uniqKey="Tyce G" first="Gertrude M." last="Tyce">Gertrude M. Tyce</name>
</author>
<author>
<name sortKey="Nickander, Kim K" sort="Nickander, Kim K" uniqKey="Nickander K" first="Kim K." last="Nickander">Kim K. Nickander</name>
</author>
<author>
<name sortKey="Petersen, Ronald C" sort="Petersen, Ronald C" uniqKey="Petersen R" first="Ronald C." last="Petersen">Ronald C. Petersen</name>
</author>
<author>
<name sortKey="Kokmen, Emre" sort="Kokmen, Emre" uniqKey="Kokmen E" first="Emre" last="Kokmen">Emre Kokmen</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:68B4CB6BF04C2B39FFD316752992C25B4225EAFB</idno>
<date when="1995" year="1995">1995</date>
<idno type="doi">10.1002/mds.870100507</idno>
<idno type="url">https://api.istex.fr/document/68B4CB6BF04C2B39FFD316752992C25B4225EAFB/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000358</idno>
<idno type="wicri:Area/Istex/Curation">000358</idno>
<idno type="wicri:Area/Istex/Checkpoint">003C85</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Ahlskog:no:evidence:for</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:8552107</idno>
<idno type="wicri:Area/PubMed/Corpus">004938</idno>
<idno type="wicri:Area/PubMed/Curation">004938</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004946</idno>
<idno type="wicri:Area/Ncbi/Merge">004A45</idno>
<idno type="wicri:Area/Ncbi/Curation">004A45</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">004A45</idno>
<idno type="wicri:doubleKey">0885-3185:1995:Ahlskog J:no:evidence:for</idno>
<idno type="wicri:Area/Main/Merge">008A16</idno>
<idno type="wicri:Area/Main/Curation">005854</idno>
<idno type="wicri:Area/Main/Exploration">005854</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease</title>
<author>
<name sortKey="Ahlskog" sort="Ahlskog" uniqKey="Ahlskog" last="Ahlskog">Ahlskog</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic Rochester, Rochester</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Uitti, Ryan J" sort="Uitti, Ryan J" uniqKey="Uitti R" first="Ryan J." last="Uitti">Ryan J. Uitti</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Mayo Clinic Jacksonville, Jacksonville, Florida</wicri:regionArea>
<placeName>
<region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Low, Phillip A" sort="Low, Phillip A" uniqKey="Low P" first="Phillip A." last="Low">Phillip A. Low</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic Rochester, Rochester</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Tyce, Gertrude M" sort="Tyce, Gertrude M" uniqKey="Tyce G" first="Gertrude M." last="Tyce">Gertrude M. Tyce</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Physiology and Biophysics, Mayo Clinic Rochester, Rochester</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Nickander, Kim K" sort="Nickander, Kim K" uniqKey="Nickander K" first="Kim K." last="Nickander">Kim K. Nickander</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic Rochester, Rochester</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Petersen, Ronald C" sort="Petersen, Ronald C" uniqKey="Petersen R" first="Ronald C." last="Petersen">Ronald C. Petersen</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic Rochester, Rochester</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Kokmen, Emre" sort="Kokmen, Emre" uniqKey="Kokmen E" first="Emre" last="Kokmen">Emre Kokmen</name>
<affiliation wicri:level="2">
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Minnesota</region>
</placeName>
<wicri:cityArea>Department of Neurology, Mayo Clinic Rochester, Rochester</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="1995-09">1995-09</date>
<biblScope unit="vol">10</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="566">566</biblScope>
<biblScope unit="page" to="573">573</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">68B4CB6BF04C2B39FFD316752992C25B4225EAFB</idno>
<idno type="DOI">10.1002/mds.870100507</idno>
<idno type="ArticleID">MDS870100507</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>5‐S‐Cysteinyl‐dopa</term>
<term>Aged</term>
<term>Alzheimer Disease (blood)</term>
<term>Alzheimer Disease (drug therapy)</term>
<term>Alzheimer Disease (metabolism)</term>
<term>Alzheimer's disease</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Brain (metabolism)</term>
<term>Carbidopa (administration & dosage)</term>
<term>Carbidopa (therapeutic use)</term>
<term>Diabetes Mellitus (blood)</term>
<term>Diabetes Mellitus (metabolism)</term>
<term>Diabetes mellitus</term>
<term>Ergolines (administration & dosage)</term>
<term>Ergolines (therapeutic use)</term>
<term>Female</term>
<term>Free Radicals</term>
<term>Humans</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (therapeutic use)</term>
<term>Lipid Peroxidation</term>
<term>Male</term>
<term>Malondialdehyde</term>
<term>Malondialdehyde (blood)</term>
<term>Malondialdehyde (metabolism)</term>
<term>Oxidant stress</term>
<term>Oxidative Stress</term>
<term>Parkinson Disease (blood)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson's disease</term>
<term>Selegiline (administration & dosage)</term>
<term>Selegiline (therapeutic use)</term>
<term>Vitamin E (administration & dosage)</term>
<term>Vitamin E (therapeutic use)</term>
<term>α‐Tocopherol</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Ergolines</term>
<term>Levodopa</term>
<term>Selegiline</term>
<term>Vitamin E</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en">
<term>Alzheimer Disease</term>
<term>Diabetes Mellitus</term>
<term>Malondialdehyde</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Alzheimer Disease</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en">
<term>Alzheimer Disease</term>
<term>Brain</term>
<term>Diabetes Mellitus</term>
<term>Malondialdehyde</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Antiparkinson Agents</term>
<term>Carbidopa</term>
<term>Ergolines</term>
<term>Levodopa</term>
<term>Selegiline</term>
<term>Vitamin E</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Aged</term>
<term>Female</term>
<term>Free Radicals</term>
<term>Humans</term>
<term>Lipid Peroxidation</term>
<term>Male</term>
<term>Oxidative Stress</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Oxidant stress secondary to dopamine metabolism has been proposed as a pathogenic factor in the development of Parkinson's disease. Biochemical abnormalities extending beyond the central nervous system have been identified in patients with this condition. Previous investigators have found abnormally elevated concentrations of the lipid peroxidation product, malondialdehyde, in the plasma and serum of patients with Parkinson's disease. We attempted to replicate these findings but controlled for other factors that could influence malondialdehyde levels. We detected no significant elevations in mean serum malondialdehyde concentrations in either levodopatreated or untreated patients with Parkinson's disease, compared to normal controls; similarly, no elevation was found in a group of patients with dementia of Alzheimer's type. On the other hand, a group of subjects with diabetes mellitus but no neurodegenerative disease had significantly elevated mean serum malondialdehyde levels, consistent with previous studies of diabetic patients. Autoxidation is one of the two major routes by which dopamine and dopa metabolism may generate oxygen free radicals. We analyzed the autoxidation product of dopa, 5‐S‐cysteinyl‐dopa, in the plasma of these same groups of patients with neurodegenerative disease and normal controls; no significant differences were identified. Serum concentrations of two other antioxidant substances, α‐tocopherol and uric acid, were also statistically similar in these groups. In conclusion, analysis of several blood products relevant to oxidant stress, including malondialdehyde, 5‐S‐cysteinyl‐dopa, α‐tocophero, and uric acid, failed to distinguish patients with Parkinson's disease or dementia of Alzheimer's type from controls.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>États-Unis</li>
</country>
<region>
<li>Floride</li>
<li>Minnesota</li>
</region>
</list>
<tree>
<country name="États-Unis">
<region name="Minnesota">
<name sortKey="Ahlskog" sort="Ahlskog" uniqKey="Ahlskog" last="Ahlskog">Ahlskog</name>
</region>
<name sortKey="Kokmen, Emre" sort="Kokmen, Emre" uniqKey="Kokmen E" first="Emre" last="Kokmen">Emre Kokmen</name>
<name sortKey="Low, Phillip A" sort="Low, Phillip A" uniqKey="Low P" first="Phillip A." last="Low">Phillip A. Low</name>
<name sortKey="Nickander, Kim K" sort="Nickander, Kim K" uniqKey="Nickander K" first="Kim K." last="Nickander">Kim K. Nickander</name>
<name sortKey="Petersen, Ronald C" sort="Petersen, Ronald C" uniqKey="Petersen R" first="Ronald C." last="Petersen">Ronald C. Petersen</name>
<name sortKey="Tyce, Gertrude M" sort="Tyce, Gertrude M" uniqKey="Tyce G" first="Gertrude M." last="Tyce">Gertrude M. Tyce</name>
<name sortKey="Uitti, Ryan J" sort="Uitti, Ryan J" uniqKey="Uitti R" first="Ryan J." last="Uitti">Ryan J. Uitti</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005854 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005854 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:68B4CB6BF04C2B39FFD316752992C25B4225EAFB
   |texte=   No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024